AbbVie Inc
Active …4AB.XETRA
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and …
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
373.75B EUR
Healthcare
Drug Manufacturers - General
Germany
EUR
Common Stock
- Open
- —
- High
- —
- Low
- —
- Close / last
- —
- Volume
- —
- Prev close
- —
- Change
- —
- Change %
- —
- Session date
- —
- Quote time
- —
PE Ratio (TTM)
68.89
Forward PE
17.36
Earnings per Share
$3.07
Dividend per Share
$6.83
Market Cap
373.75B
EBITDA
30.76B
Profit Margin
0.0980%
Dividend Yield
0.03%
Price / Sales (TTM)
5.800x
EV / Revenue
7.690x
EV / EBITDA
25.420x
Revenue Growth (YoY)
0.102%
Earnings Growth (YoY)
2.904%
Address
1 North Waukegan Road
North Chicago
, IL
60064-6400
United States
Phone
847 932 7900Website
https://www.abbvie.comEmployees
57000
Dr. Azita Saleki Ph.D.
Executive VP & COO
Born 1963
Dr. Roopal B. Thakkar M.D.
Executive VP of Research & Development and Chief Scientific Officer
Born 1972
Mr. Demetris D. Crum
Executive VP & Chief Human Resources Officer
Born 1981
Mr. Jeffrey Ryan Stewart
Executive VP & Chief Commercial Officer
Born 1969
Mr. Perry C. Siatis
Executive VP, General Counsel & Secretary
Born 1975
Mr. Robert A. Michael CPA
CEO & Chairman of the Board
Born 1970
Mr. Scott T. Reents
Executive VP & CFO
Born 1968
Mr. Wulff-Erik von Borcke
Senior VP & President of Oncology
Ms. Elizabeth Shea
Senior Vice President of Investor Relations
Ms. Linda Ray
Senior VP & Chief Information Officer
2026-07-31
2026-10-29
Recent quarters & estimate trends
View full earnings (44)| Period | EPS Act. | EPS Est. | Surprise |
|---|---|---|---|
| Sep 2026 | — | 3.87 | — |
| Jun 2026 | 1.75 | 3.65 | -52.09% |
| Mar 2026 | 0.33 | 2.69 | -87.55% |
| Dec 2025 | 0.88 | 2.65 | -66.81% |
| Sep 2025 | 0.09 | 1.78 | -95.22% |
| Jun 2025 | 0.46 | 2.91 | -84.13% |
| Mar 2025 | 0.69 | — | — |
| Dec 2024 | -0.01 | — | — |
Estimate trends
Dec 2027
—
Dec 2026
—
Sep 2026
—
Jun 2026
—